Latest Manufacturing Investment News

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

PMET Resources has completed a positive lithium-only feasibility study for its Shaakichiuwaanaan Project in Quebec, confirming technical and economic viability for a large-scale spodumene concentrate operation with a targeted final investment decision in 2027.

Metals Australia Ltd reports key milestones in its Lac Carheil Graphite Project, achieving battery-grade spherical graphite purity and selecting Sept-Îles as the preferred site for its Battery Anode Material plant.

Amaero Ltd has secured A$50 million through a share placement and plans a further A$3 million via a Share Purchase Plan to fast-track growth initiatives aligned with U.S. defense and manufacturing re-shoring priorities.

Amotiv Limited reported modest revenue growth and a slight EBITA decline in FY25, offset by a significant non-cash impairment and strong capital returns. The company anticipates growth in FY26 amid ongoing market headwinds.

Amotiv Limited reported a modest 1% revenue increase for FY25 alongside a significant $190 million impairment, maintaining shareholder returns with a stable dividend. The company signals cautious optimism for FY26 despite ongoing market headwinds.